arrow
I

Iyama, Satoshi

department of hematology
H指数:0
被引数:4

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net

与第一周期阿扎胞苷-维奈克拉组合中14天、21天或标准28天维奈克拉治疗相比,在未经治疗的急性髓系白血病中具有可比的结果:来自北海道白血病网的现实世界经验

2025-07-030
OAAI
Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study
2025-02-080
OAAI
FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML

FLT3抑制剂和造血干细胞移植可延长FLT3-ITD-positive AML患者的生存期

2024-11-301
PRE
Evaluation of Venetoclax Duration in Venetoclax-Azacitidine Regimen for Untreated Acute Myeloid Leukemia: Real World Experience from Hokkaido Leukemia Net

评估Venetoclax持续时间在Venetoclax-Azacitidine方案中对初治急性髓系白血病的影响:来自Hokkaido Leukemia Net的真实世界经验

BLOOD
IF23.1
2024-11-051
PRE
Intravenous Infusion of Autologous Mesenchymal Stem Cells Expanded in Auto Serum for Chronic Spinal Cord Injury Patients: A Case Series

静脉输注自体血清扩增的间充质干细胞治疗慢性脊髓损伤患者: 病例系列

2024-10-111
OAAI
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study

Anti-CD38抗体isatuximab单药治疗日本复发/难治性多发性骨髓瘤患者: 1/2期岛屿研究的更新

2022-12-150
OAAI
Possible clinical outcomes using early enteral nutrition in individuals with allogeneic hematopoietic stem cell transplantation: A single-center retrospective study

早期肠内营养对异基因造血干细胞移植患者可能的临床结局: 一项单中心回顾性研究

2021-03-019
PREAI
DPP8 is a novel therapeutic target for multiple myeloma
2019-12-0226
OAAI
Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells

eribulin加AKT抑制剂的组合在软组织肉瘤细胞中引起协同细胞毒性

2019-04-0815
OAAI